NIOX vs. MXCT, EKF, CREO, BVXP, BMK, TSTL, APH, OXB, HVO, and AVCT
Should you be buying NIOX Group stock or one of its competitors? The main competitors of NIOX Group include MaxCyte (MXCT), EKF Diagnostics (EKF), Creo Medical Group (CREO), Bioventix (BVXP), Benchmark (BMK), Tristel (TSTL), Alliance Pharma (APH), Oxford Biomedica (OXB), hVIVO (HVO), and Avacta Group (AVCT). These companies are all part of the "medical" sector.
MaxCyte (LON:MXCT) and NIOX Group (LON:NIOX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership, community ranking and valuation.
MaxCyte received 152 more outperform votes than NIOX Group when rated by MarketBeat users. However, 100.00% of users gave NIOX Group an outperform vote while only 68.92% of users gave MaxCyte an outperform vote.
In the previous week, MaxCyte had 1 more articles in the media than NIOX Group. MarketBeat recorded 1 mentions for MaxCyte and 0 mentions for NIOX Group. NIOX Group's average media sentiment score of 0.00 equaled MaxCyte'saverage media sentiment score.
MaxCyte has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, NIOX Group has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.
NIOX Group has a consensus price target of GBX 77, indicating a potential upside of 16.31%. Given MaxCyte's higher probable upside, analysts clearly believe NIOX Group is more favorable than MaxCyte.
NIOX Group has a net margin of 29.08% compared to NIOX Group's net margin of -91.85%. MaxCyte's return on equity of 11.47% beat NIOX Group's return on equity.
76.7% of MaxCyte shares are held by institutional investors. Comparatively, 29.9% of NIOX Group shares are held by institutional investors. 1.3% of MaxCyte shares are held by company insiders. Comparatively, 54.2% of NIOX Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
NIOX Group has lower revenue, but higher earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.
Summary
NIOX Group beats MaxCyte on 10 of the 16 factors compared between the two stocks.
Get NIOX Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for NIOX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NIOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NIOX Group Competitors List
Related Companies and Tools
